Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant – Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 140 countries. Last year, more than 10 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #4 (Sell) but that could change following its positive fourth-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.31 per share. Medtronic’s adjusted earnings per share of $1.33 exceeded this estimate by 1.5%.
Full year adjusted earnings came in at $4.60 per share which marginally beats the Zacks Consensus Estimate of $4.58
Revenues: Medtronic posted revenues of $7.91 billion, exceeding the Zacks Consensus Estimate for revenues of $7.85 billion.
Full year revenues came in at $29.71 billion which is ahead of the Zacks Consensus Estimate of $29.64 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 5% at Constant exchange Rate (CER) to $2.84 billion, while revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.60 billion. On the other hand, revenues from Restorative Therapies Group rose 5% at CER to $1.95 billion, while revenues from Diabetes Group grew 4% at CER to $512 million.
Major Factors: Medtronic reported impressive fourth quarter fiscal 2017 results with both top-line and bottom-line exceeding the Zacks Consensus Estimate. The company’s year over year top line performance was also impressive across all business groups. The company provided its initial fiscal year 2018 revenue and earnings per share growth guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant – Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 140 countries. Last year, more than 10 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #4 (Sell) but that could change following its positive fourth-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.31 per share. Medtronic’s adjusted earnings per share of $1.33 exceeded this estimate by 1.5%.
Full year adjusted earnings came in at $4.60 per share which marginally beats the Zacks Consensus Estimate of $4.58
Revenues: Medtronic posted revenues of $7.91 billion, exceeding the Zacks Consensus Estimate for revenues of $7.85 billion.
Full year revenues came in at $29.71 billion which is ahead of the Zacks Consensus Estimate of $29.64 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 5% at Constant exchange Rate (CER) to $2.84 billion, while revenues from Minimally Invasive Therapies Group increased 6% at CER to $2.60 billion. On the other hand, revenues from Restorative Therapies Group rose 5% at CER to $1.95 billion, while revenues from Diabetes Group grew 4% at CER to $512 million.
Major Factors: Medtronic reported impressive fourth quarter fiscal 2017 results with both top-line and bottom-line exceeding the Zacks Consensus Estimate. The company’s year over year top line performance was also impressive across all business groups. The company provided its initial fiscal year 2018 revenue and earnings per share growth guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MDT - FREE